IDEAS home Printed from https://ideas.repec.org/a/abf/journl/v47y2022i5p38859-38869.html
   My bibliography  Save this article

Efficacy and Safety of Guluronic Acid (G2013) in a Randomized, Controlled Phase II Clinical Trial on Patients with Multiple Sclerosis

Author

Listed:
  • Payam Saadat

    (Mobility Impairment Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran)

  • Masoomeh Noorbakhsh

    (Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran)

  • Nahid Beladi Moghadam

    (Department of Neurology, Imam Hossein Hospital, Shahid Beheshti University of Medical Science, Tehran, Iran)

  • Dmitry Babarykin

    (Institute of Innovative Biomedical Technology Ltd, Riga, Latvia)

  • Galina Smirnova

    (Institute of Innovative Biomedical Technology Ltd, Riga, Latvia
    Institute of Biology of the University of Latvia, Riga, Latvia)

  • Soheil Najaf

    (Institute of Innovative Biomedical Technology Ltd, Riga, Latvia
    Institute of Biology of the University of Latvia, Riga, Latvia)

  • Mostafa Hosseini

    (Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran)

  • Abbas Mirshafiey

    (Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
    Livonian Biotech Millennium Ltd, Riga, LV-1013, Latvia)

Abstract

The α-L-guluronic acid (G2013) as a new anti-inflammatory drug with immunomodulatory property, patented (PCT/EP2017/067920), showed positive effects in experimental models of multiple sclerosis (MS). In this clinical trial, our aim was to evaluate 6 months efficacy and safety outcomes in MS treated patients with guluronic acid compared to the conventional drug.

Suggested Citation

  • Payam Saadat & Masoomeh Noorbakhsh & Nahid Beladi Moghadam & Dmitry Babarykin & Galina Smirnova & Soheil Najaf & Mostafa Hosseini & Abbas Mirshafiey, 2022. "Efficacy and Safety of Guluronic Acid (G2013) in a Randomized, Controlled Phase II Clinical Trial on Patients with Multiple Sclerosis," Biomedical Journal of Scientific & Technical Research, Biomedical Research Network+, LLC, vol. 47(5), pages 38859-38869, December.
    • Handle: RePEc:abf:journl:v:47:y:2022:i:5:p:38859-38869
    DOI: 10.26717/BJSTR.2022.47.007552
    as

    Download full text from publisher

    File URL: https://biomedres.us/pdfs/BJSTR.MS.ID.007552.pdf
    Download Restriction: no
    File URL: https://biomedres.us/fulltexts/BJSTR.MS.ID.007552.php
    Download Restriction: no
    File URL: https://libkey.io/10.26717/BJSTR.2022.47.007552?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:abf:journl:v:47:y:2022:i:5:p:38859-38869. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Angela Roy (email available below). General contact details of provider: .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.